Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

A fully replication-competent adenovirus vector with enhanced oncolytic properties

Cancer Gene Therapy volume 17, pages 761–770 (2010)Cite this article

Subjects

Abstract

We have studied the oncolytic efficacy of two adenovirus vectors named KD3 and INGN 007, which differ from each other only in that whereas KD3 has two small deletions in its e1a gene that restrict its replication to rapidly cycling cells, INGN 007 has wild-type e1a gene. Both vectors overexpress the adenovirus death protein (ADP). Both KD3 and INGN 007 effectively suppressed the growth of subcutaneous human A549 and Hep3B tumors in nude mice upon intratumoral injection, and contained the growth of subcutaneous LNCaP tumors after intravenous injection, making some tumors shrink or disappear. However, in a more demanding model, intravenous injections of neither KD3 nor wild-type Ad5 were effective against subcutaneous A549 tumors, whereas INGN 007 increased the mean survival time by 35%. INGN 007 was also effective in suppressing tumor growth in a challenging A549 orthotopic lung cancer model. INGN 007 was superior to dl1520 (ONYX-015) in repressing subcutaneous A549 tumors. Our results suggest that vectors such as INGN 007 might provide better antitumor efficacy in the clinic as well.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Cattaneo R, Miest T, Shashkova EV, Barry MA . Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6: 529–540.

    Article  CAS  Google Scholar 

  2. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373–376.

    Article  CAS  Google Scholar 

  3. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH . A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323–1333.

    Article  CAS  Google Scholar 

  4. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR . Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559–2563.

    CAS  PubMed  Google Scholar 

  5. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR . The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59: 4200–4203.

    CAS  PubMed  Google Scholar 

  6. Lichtenstein DL, Wold WSM . Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther 2004; 11: 819–829.

    Article  CAS  Google Scholar 

  7. Lin E, Nemunaitis J . Oncolytic viral therapies. Cancer Gene Ther 2004; 11: 643–664.

    Article  CAS  Google Scholar 

  8. Jia H, Kling J . China offers alternative gateway for experimental drugs. Nat Biotechnol 2006; 24: 117–118.

    Article  CAS  Google Scholar 

  9. Doronin K, Toth K, Kuppuswamy M, Krajcsi P, Tollefson AE, Wold WSM . Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 2003; 305: 378–387.

    Article  CAS  Google Scholar 

  10. Berk AJ . Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 2005; 24: 7673–7685.

    Article  CAS  Google Scholar 

  11. Gonzalez R, Huang W, Finnen R, Bragg C, Flint SJ . Adenovirus E1B 55-kilodalton protein is required for both regulation of mRNA export and efficient entry into the late phase of infection in normal human fibroblasts. J Virol 2006; 80: 964–974.

    Article  CAS  Google Scholar 

  12. Vaillancourt M, Atencio I, Quijano E, Howe JA, Ramachandra M . Inefficient killing of quiescent human epithelial cells by replicating adenoviruses: potential implications for their use as oncolytic agents. Cancer Gene Ther 2005; 12: 691–698.

    Article  CAS  Google Scholar 

  13. Barton KN, Paielli D, Zhang Y, Koul S, Brown SL, Lu M et al. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol Ther 2006; 13: 347–356.

    Article  CAS  Google Scholar 

  14. Wein LM, Wu JT, Kirn DH . Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res 2003; 63: 1317–1324.

    CAS  PubMed  Google Scholar 

  15. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WSM . Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 2000; 74: 6147–6155.

    Article  CAS  Google Scholar 

  16. Toth K, Tarakanova V, Doronin K, Ward P, Kuppuswamy M, Locke JL et al. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Ther 2003; 10: 193–200.

    Article  CAS  Google Scholar 

  17. Lichtenstein DL, Spencer JF, Doronin K, Patra D, Meyer J, Shashkova EV et al. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther 2009; 16: 644–654.

    Article  CAS  Google Scholar 

  18. Ying B, Toth K, Spencer JF, Meyer J, Tollefson AE, Patra D et al. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Ther 2009; 16: 625–637.

    Article  CAS  Google Scholar 

  19. Barker DD, Berk AJ . Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987; 156: 107–121.

    Article  CAS  Google Scholar 

  20. Tollefson AE, Kuppuswamy M, Shashkova EV, Doronin K, Wold WSM . Preparation and titration of CsCl-banded adenovirus stocks. Methods Mol Med 2007; 130: 223–235.

    CAS  PubMed  Google Scholar 

  21. Kuppuswamy M, Spencer JF, Doronin K, Tollefson AE, Wold WS, Toth K . Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Therapy 2005; 12: 1608–1617.

    Article  CAS  Google Scholar 

  22. Toth K, Spencer JF, Dhar D, Sagartz JE, Buller RM, Painter GR et al. Hexadecyloxypropyl-cidofovir CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci USA 2008; 105: 7293–7297.

    Article  CAS  Google Scholar 

  23. Toth K, Spencer JF, Tollefson AE, Kuppuswamy M, Doronin K, Lichtenstein DL et al. Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum Gene Ther 2005; 16: 139–146.

    Article  CAS  Google Scholar 

  24. Dhar D, Spencer JF, Toth K, Wold WSM . Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J Virol 2009; 83: 2130–2139.

    Article  CAS  Google Scholar 

  25. Dhar D, Spencer JF, Toth K, Wold WS . Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Mol Ther 2009; 17: 1724–1732.

    Article  CAS  Google Scholar 

  26. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270–1276.

    Article  CAS  Google Scholar 

  27. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips N, Wold WSM . Immunosuppression enhances oncolytic adenovirus replication and anti tumor efficacy in the Syrian hamster model. Mol Ther 2008; 16: 1665–1673.

    Article  CAS  Google Scholar 

  28. Hartline CB, Gustin KM, Wan WB, Ciesla SL, Beadle JR, Hostetler KY et al. Ether lipid–ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis 2005; 191: 396–399.

    Article  CAS  Google Scholar 

  29. Dilley J, Reddy S, Ko D, Nguyen N, Rojas G, Working P et al. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther 2005; 12: 715–722.

    Article  CAS  Google Scholar 

  30. Huang P, Watanabe M, Kaku H, Kashiwakura Y, Chen J, Saika T et al. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent OBP-301, in a mouse prostate cancer model. Cancer Gene Ther 2008; 15: 315–322.

    Article  CAS  Google Scholar 

  31. Ryan PC, Jakubczak JL, Stewart DA, Hawkins LK, Cheng C, Clarke LM et al. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer. Cancer Gene Ther 2004; 11: 555–569.

    Article  CAS  Google Scholar 

  32. Spencer JF, Sagartz JE, Wold WSM, Toth K . New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster. Cancer Gene Ther 2009; 16: 912–922.

    Article  CAS  Google Scholar 

  33. Alemany R . Cancer selective adenoviruses. Mol Aspects Med 2007; 28: 42–58.

    Article  CAS  Google Scholar 

  34. Kumar S, Gao L, Yeagy B, Reid T . Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008; 10: 371–379.

    PubMed  Google Scholar 

  35. Lichtenstein DL, Toth K, Doronin K, Tollefson AE, Wold WSM . Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol 2004; 23: 75–111.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This research was supported by Grant CA118022 from the National Institutes of Health.

Author information

Authors and Affiliations

  1. Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St Louis, MO, USA

    K Toth, M Kuppuswamy, E V Shashkova, J F Spencer & W S M Wold

Authors
  1. K Toth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Kuppuswamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E V Shashkova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J F Spencer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W S M Wold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W S M Wold.

Ethics declarations

Competing interests

Some of the funding for the research was provided by VirRx Inc. WSMW and KT own stock in VirRx Inc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Toth, K., Kuppuswamy, M., Shashkova, E. et al. A fully replication-competent adenovirus vector with enhanced oncolytic properties. Cancer Gene Ther 17, 761–770 (2010). https://doi.org/10.1038/cgt.2010.33

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2010.33

Keywords

This article is cited by

Search

Advanced search

Quick links